Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$464.92 USD
-12.98 (-2.72%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $464.91 -0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for Vertex Pharmaceuticals Incorporated falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 11,218 | 10,779 | 7,525 | 6,659 | 3,808 |
Receivables | 1,563 | 1,442 | 1,137 | 885 | 634 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 739 | 461 | 353 | 281 | 168 |
Other Current Assets | 624 | 554 | 546 | 308 | 214 |
Total Current Assets | 14,144 | 13,235 | 9,561 | 8,133 | 4,823 |
Net Property & Equipment | 1,159 | 1,108 | 1,094 | 959 | 745 |
Investments & Advances | 2,498 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 1,812 | 1,247 | 935 | 883 | 1,191 |
Intangibles | 1,928 | 1,692 | 1,402 | 1,402 | 1,402 |
Deposits & Other Assets | 895 | 522 | 111 | 49 | 158 |
Total Assets | 22,730 | 18,151 | 13,433 | 11,752 | 8,318 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 365 | 304 | 195 | 155 | 88 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2,655 | 2,127 | 1,679 | 1,405 | 1,117 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 527 | 312 | 268 | 317 | 130 |
Total Current Liabilities | 3,547 | 2,742 | 2,142 | 1,878 | 1,335 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 376 | 431 | 510 | 539 | 539 |
Other Non-Current Liabilities | 878 | 686 | 303 | 298 | 360 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 5,150 | 4,238 | 3,333 | 3,065 | 2,233 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 3 | 3 | 3 | 3 | 3 |
Capital Surplus | 7,450 | 7,387 | 6,881 | 7,894 | 7,938 |
Retained Earnings | 10,142 | 6,523 | 3,201 | 859 | -1,853 |
Other Equity | -14 | 1 | 16 | -68 | -2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 17,580 | 13,913 | 10,100 | 8,687 | 6,085 |
Total Liabilities & Shareholder's Equity | 22,730 | 18,151 | 13,433 | 11,752 | 8,318 |
Total Common Equity | 17,580 | 13,913 | 10,100 | 8,687 | 6,085 |
Shares Outstanding | 257.60 | 256.60 | 254.20 | 260.00 | 257.10 |
Book Value Per Share | 68.25 | 54.22 | 39.73 | 33.41 | 23.67 |
Fiscal Year End for Vertex Pharmaceuticals Incorporated falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 5,796 | 10,171 | 11,218 | 11,928 | 11,236 |
Receivables | 1,656 | 1,793 | 1,563 | 1,539 | 1,556 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 915 | 813 | 739 | 689 | 604 |
Other Current Assets | 575 | 511 | 624 | 540 | 477 |
Total Current Assets | 8,942 | 13,289 | 14,144 | 14,696 | 13,873 |
Net Property & Equipment | 1,201 | 1,173 | 1,159 | 1,124 | 1,122 |
Investments & Advances | 4,393 | 4,381 | 2,498 | 1,700 | 1,357 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 2,186 | 1,963 | 1,812 | 1,729 | 1,538 |
Intangibles | 1,926 | 1,923 | 1,928 | 1,692 | 1,692 |
Deposits & Other Assets | 916 | 876 | 895 | 475 | 443 |
Total Assets | 20,132 | 23,917 | 22,730 | 21,726 | 20,349 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 328 | 351 | 365 | 376 | 363 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2,940 | 2,796 | 2,655 | 2,907 | 2,598 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 279 | 649 | 527 | 316 | 391 |
Total Current Liabilities | 3,547 | 3,796 | 3,547 | 3,599 | 3,352 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 347 | 362 | 376 | 390 | 404 |
Other Non-Current Liabilities | 877 | 878 | 869 | 759 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 5,357 | 5,371 | 5,150 | 5,213 | 4,879 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 3 | 3 | 3 | 3 | 3 |
Capital Surplus | 7,101 | 7,285 | 7,450 | 7,340 | 7,369 |
Retained Earnings | 7,648 | 11,242 | 10,142 | 9,174 | 8,138 |
Other Equity | 23 | 17 | -14 | -3 | -40 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 14,775 | 18,547 | 17,580 | 16,513 | 15,470 |
Total Liabilities & Shareholder's Equity | 20,132 | 23,917 | 22,730 | 21,726 | 20,349 |
Total Common Equity | 14,775 | 18,547 | 17,580 | 16,513 | 15,470 |
Shares Outstanding | 258.00 | 258.40 | 257.60 | 258.10 | 257.50 |
Book Value Per Share | 57.27 | 71.77 | 68.25 | 63.98 | 60.08 |